Back

Impact of guideline-directed medical therapies on clinical and economic outcomes in nonobstructive hypertrophic cardiomyopathy: analysis of data from a multinational cross-sectional survey

10 May 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Paulos Gebrehiwet

Cytokinetics, Incorporated, South San Francisco (United States of America)

6 More presentations in this session

Presentation thumbnail
Time to consider atrial and diastolic function as key drivers of major adverse cardiovascular events in hypertrophic cardiomyopathy
Doctor A. Martins (Leiria, PT)
Abstract Slides
Presentation thumbnail
Clinical and economic burden in NYHA class I versus II-IV hypertrophic cardiomyopathy: real-world survey data from the United States of America
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract Slides
Presentation thumbnail
Differentiating hypertrophy phenocopies from afterload-induced left ventricular hypertrophy using artificial intelligence-enabled electrocardiography
Mr D. Ahmetagic (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Patient characteristics in pediatric hypertrophic cardiomyopathy: insights from an observational study
Mrs X. Pan (Princeton, US)
Abstract Slides
Presentation thumbnail
Sex-related differences in HCM: cardiogenetics, disease severity and major outcomes
Doctor R. Esculudes Dos Santos Ferrao Gomes (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2026

10 May 2026 10:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources